Literature DB >> 6365100

Long-term inhibition of ovulation by a GnRH-antagonist at low dose level.

M Kovacs, I Mezo, B Flerko, I Teplan, K Nikolics.   

Abstract

Ac-D-Trp1,3, D-Cpa2, D-Lys6, D-Ala10-GnRH has been prepared by solid phase synthesis. The peptide was found to completely inhibit ovulation when administered on proestrus day in a dose of 1.5 microgram/rat, s.c. The peptide completely inhibited ovulation for a period corresponding to three to four cycles when administered daily in a dose of 5 micrograms/rat, s.c. and caused 70% inhibition of ovulation in a dose of 3 micrograms/rat.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6365100     DOI： 10.1016/0006-291x(84)91108-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  3 in total

1.  Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.

Authors:  I Pályi; B Vincze; S Lovas; I Mezö; J Pató; A Kálnay; G Turi; D Gaál; R Mihalik; I Péter; I Teplán; R F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues.

Authors:  A Kálnay; I Pályi; B Vincze; R Mihalik; I Mezõ; J Pató; J Seprõdi; S Lovas; R F Murphy
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

3.  Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts.

Authors:  B Vincze; I Pályi; D Daubner; A Kálnay; G Mezö; F Hudecz; M Szekerke; I Teplán; I Mezö
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.